CompletedNCT03902613
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolarity
Medication studyAges 18–50United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- New York, United StatesSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: February 7, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03902613
- Official title
Show the full official title
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
Recruitment & locations
CompletedNew York
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me